HomeCompareDCHIF vs PFE

DCHIF vs PFE: Dividend Comparison 2026

DCHIF yields 2.25% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCHIF wins by $107.19M in total portfolio value
10 years
DCHIF
DCHIF
● Live price
2.25%
Share price
$0.34
Annual div
$0.01
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.24M
Annual income
$98,793,237.10
Full DCHIF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DCHIF vs PFE

📍 DCHIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCHIFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCHIF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCHIF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCHIF
Annual income on $10K today (after 15% tax)
$191.08/yr
After 10yr DRIP, annual income (after tax)
$83,974,251.54/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DCHIF beats the other by $83,951,931.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCHIF + PFE for your $10,000?

DCHIF: 50%PFE: 50%
100% PFE50/50100% DCHIF
Portfolio after 10yr
$53.64M
Annual income
$49,409,747.91/yr
Blended yield
92.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DCHIF
No analyst data
Altman Z
2.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCHIF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCHIFPFE
Forward yield2.25%6.13%
Annual dividend / share$0.01$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$107.24M$49.6K
Annual income after 10y$98,793,237.10$26,258.71
Total dividends collected$106.57M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DCHIF vs PFE ($10,000, DRIP)

YearDCHIF PortfolioDCHIF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,150$449.61$9,153$693.39+$2.0KDCHIF
2$12,867$937.01$8,593$849.25+$4.3KDCHIF
3$15,789$2,021.21$8,336$1,066.78+$7.5KDCHIF
4$21,530$4,635.87$8,437$1,384.80+$13.1KDCHIF
5$34,853$11,815.94$9,013$1,875.40+$25.8KDCHIF
6$73,046$35,752.85$10,306$2,680.72+$62.7KDCHIF
7$218,217$140,058.57$12,820$4,101.38+$205.4KDCHIF
8$1,015,572$782,079.20$17,673$6,826.70+$997.9KDCHIF
9$7,889,938$6,803,276.00$27,543$12,591.86+$7.86MDCHIF
10$107,235,471$98,793,237.10$49,560$26,258.71+$107.19MDCHIF

DCHIF vs PFE: Complete Analysis 2026

DCHIFStock

Digital China Holdings Limited, an investment holding company, provides big data products and solutions for government and enterprise customers primarily in Mainland China. The Big Data Products and Solutions segment sells data software products focused on spatial-temporal big data and artificial intelligence. This segment offers data fabric comprising Yan Cloud DaaS, a software platform that supports data sharing, interoperability, and integration of isolated digital islands; and Sysnet, an integration platform that integrates various data, applications, and services. It also provides data hub, including data management, security, innovation, and aggregation products; and digital twin, which constructs a digital replica of the physical city, as well as data solutions for city and supply chain digital native transformation, and fintech. The Software and Operating Services segment offers end-to-end data-enabled supply chain operating services, as well as software development, testing, operation, and maintenance services. The Traditional Services segment provides systems integration services, e-commerce supply chain services, and software and operating services. The segment also engages in the investments, property sales and rental, and other businesses. It also engages in provision of logistics, systems integration, technical, network optimization, rural agricultural internet, data processing and manpower outsourcing, and cloud application system services; development and construction of science and technology park; finance lease and property development business; operation of sm@rt city platform; and sale of financial specialized equipment and surveying service software. In addition, the company offers Quattro, a touchless multi-biometric access control reader; and Aibion Trio, a contactless multi-biometric access control solution. Digital China Holdings Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Full DCHIF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DCHIF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCHIF vs SCHDDCHIF vs JEPIDCHIF vs ODCHIF vs KODCHIF vs MAINDCHIF vs JNJDCHIF vs MRKDCHIF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.